<DOC>
	<DOCNO>NCT01894789</DOCNO>
	<brief_summary>Ticagrelor one 3 anti-platelet medication use patient acute coronary syndrome ( ACS ) prevent clot formation ischemic damage myocardial tissue . Overall benefit one drug neutral generally unstable population . In pre-clinical trial , ticagrelor show secondary effect , involve release adenosine heart muscle demand blood increase due stress condition . Blood flow increase , potentially prevent potential damage . This study compare ticagrelor , currently approve use ACS patient , clopidogrel measure myocardial blood flow ( MBF ) stress validate phenomenon . The effect blood flow measurable use two specific dos adenosine pharmacologic stress correlate measurement blood flow use positron emission tomography ( PET ) nuclear imaging . This study hypothesize increase MBF intermediate dose adenosine infusion great ticagrelor treat subject compare clopidogrel treat subject</brief_summary>
	<brief_title>Ticagrelor v Clopidogrel Effect MFR CAD Population</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age â‰¥ 18 year old 2 . Stable coronary artery disease stable medical treatment . 3 . BMI equal less 30 kg/m2 4 . No clinically significant abnormality baseline laboratory work 5 . No clinically significant arrhythmias baseline 12lead electrocardiogram 6 . Female subject must postmenopausal , surgically sterilize negative urine beta human chorionic gonadotropin pregnancy test initial screen maintain effective contraceptive method throughout trial 7 day follow end dose treatment . 1 . Any contraindication use clopidogrel , ticagrelor and/or ASA . 2 . Oral anticoagulation therapy . 3 . History intracranial bleeding . 4 . Recent active pathological bleeding , peptic ulcer . 5 . Moderate severe hepatic impairment . 6 . History risk bradycardia . 7 . Known second thirddegree AV block without pacemaker 8 . Dyspnea ( NYHA III/IV ) , wheeze asthma COPD . 9 . Coronary artery bypass graft ( CABG ) surgery within 90 day prior screen time consent . 10 . Percutaneous coronary intervention ( PCI ) within 90 day prior screen time follow consent . 11 . Acute myocardial infarction acute coronary syndrome within 60 day prior screen time follow consent . 12 . Any scheduled surgery trial period , include dental . 13 . Concomitant therapy strong cytochrome CYP 3A inhibitor inducer . 14 . Recent use dipyridamole , dipyridamolecontaining medication ( e.g . Aggrenox ) 15 . Known hypersensitivity investigational drug component . 16 . Known hypersensitivity adenosine . 17 . Lactose intolerance 18 . Breastfeeding pregnancy . 19 . Claustrophobia inability lie still supine position 20 . Unwillingness provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>myocardial blood flow</keyword>
	<keyword>myocardial perfusion imaging</keyword>
	<keyword>myocardial blood flow reserve</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>adenosine</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
</DOC>